Abstract
HCV infection is related to hepatic disease and mixed cryoglobulinaemia (MC). Renal involvement is reported in one third of cryoglobulinaemic patients. The combination of HCV related MC with renal involvement has been associated with poor survival and identified as Hepatitis C Virus Risk Syndrome (HCV RS). Here we describe antiviral treatment and management of side effects (anaemia and neutropenia) with RHuEpo and G CSF in a rare case of HCV RS.
MeSH terms
-
Anemia / drug therapy
-
Anemia / virology
-
Antiviral Agents / therapeutic use
-
Cryoglobulinemia / complications
-
Cryoglobulinemia / virology*
-
Drug Therapy, Combination
-
Erythropoietin / therapeutic use*
-
Glomerulonephritis, Membranoproliferative / complications
-
Glomerulonephritis, Membranoproliferative / virology*
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Hepatitis C / complications*
-
Hepatitis C / drug therapy*
-
Humans
-
Interferons / therapeutic use
-
Liver Cirrhosis / drug therapy
-
Liver Cirrhosis / virology
-
Male
-
Middle Aged
-
Neutropenia / drug therapy
-
Neutropenia / etiology
-
Recombinant Proteins / therapeutic use
-
Ribavirin / therapeutic use
-
Risk Factors
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Recombinant Proteins
-
Erythropoietin
-
Granulocyte Colony-Stimulating Factor
-
Ribavirin
-
Interferons